Fractional Dosing of Yellow Fever Live Attenuated 17D Vaccine: A Perspective

References

• Johansson MA, Vasconcelos PFC, Staples JE. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. Trans R Soc Trop Med Hyg. 2014;108(8):482–487. doi:10.1093/trstmh/tru092
   PubMed Web of Science ®Google Scholar
• Beck AS, Barrett AD. Current status and future prospects of yellow fever vaccines. Expert Rev Vaccines. 2015;14(11):1479–1492. doi:10.1586/14760584.2015.1083430
   PubMed Web of Science ®Google Scholar
• Gaythorpe KA, Hamlet A, Jean K, et al. The global burden of yellow fever. eLife. 2021;10:e64670. doi:10.7554/eLife.64670
   PubMed Web of Science ®Google Scholar
• Yellow fever. Available from: https://www.who.int/news-room/fact-sheets/detail/yellow-fever. Accessed January 25, 2023.
   Google Scholar
• Haddow AJ. X.—The Natural History of Yellow Fever in Africa. Proc Sect B Biol. 1969;70(3):191–227. doi:10.1017/S0080455X00001338
   Google Scholar
• Ellis BR, Barrett ADT. The enigma of yellow fever in East Africa. Rev Med Virol. 2008;18(5):331–346. doi:10.1002/rmv.584
   PubMed Web of Science ®Google Scholar
• List of Prequalified Vaccines. WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control); 2019. https://extranet.who.int/pqweb/vaccines/list-prequalified-vaccines. Available from: Accessed January 25, 2023.
   Google Scholar
• Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines, Annex 5, TRS No 978; 2013. Available from: https://www.who.int/publications/m/item/yellow-fever-vaccines-live-attenuated-annex-5-trs-no-978. Available from: Accessed September 20, 2023.
   Google Scholar
• Coulange Bodilis H, Benabdelmoumen G, Gergely A, et al. Persistance à long terme des anticorps neutralisants de la fièvre jaune chez les personnes âgées de 60 ans et plus. Bull Soc Pathol Exot. 2011;104(4):260–265. doi:10.1007/s13149-011-0135-7
   PubMedGoogle Scholar
• Staples JE, Barrett ADT, Wilder-Smith A, Hombach J. Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection. Npj Vaccines. 2020;5(1):54. doi:10.1038/s41541-020-0205-6
   PubMed Web of Science ®Google Scholar
• Wieten RW, Jonker EFF, van Leeuwen EMM, et al. A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination. PLoS One. 2016;11(3):e0149871. doi:10.1371/journal.pone.0149871
   PubMed Web of Science ®Google Scholar
• Barrett ADT. The reemergence of yellow fever. Science. 2018;361(6405):847–848. doi:10.1126/science.aau8225
   PubMed Web of Science ®Google Scholar
• Song R, Guan S, Lee SS, et al. Late or Lack of Vaccination Linked to Importation of Yellow Fever from Angola to China. Emerg Infect Dis. 2018;24(7):1383–1386. doi:10.3201/eid2407.171868
   PubMed Web of Science ®Google Scholar
• Kwagonza L, Masiira B, Kyobe-Bosa H, et al. Outbreak of yellow fever in central and southwestern Uganda, February–may 2016. BMC Infect Dis. 2018;18(1):548. doi:10.1186/s12879-018-3440-y
   PubMed Web of Science ®Google Scholar
• Ingelbeen B, Weregemere NA, Noel H, et al. Urban yellow fever outbreak—Democratic Republic of the Congo, 2016: towards more rapid case detection. PLoS Negl Trop Dis. 2018;12(12):e0007029. doi:10.1371/journal.pntd.0007029
   PubMed Web of Science ®Google Scholar
• Epidemiological Update: yellow Fever. 1 Pan American Health Organization / World Health Organization; 2018. Available from: http://bit.ly/2BympPo. Accessed July 6, 2022.
   Google Scholar
• Nomhwange T, Jean Baptiste AE, Ezebilo O, et al. The resurgence of yellow fever outbreaks in Nigeria: a 2-year review 2017–2019. BMC Infect Dis. 2021;21(1):1054. doi:10.1186/s12879-021-06727-y
   PubMed Web of Science ®Google Scholar
• Lindsey NP, Horton J, Barrett ADT, et al. Yellow fever resurgence: an avoidable crisis? Npj Vaccines. 2022;7(1):137. doi:10.1038/s41541-022-00552-3
   PubMed Web of Science ®Google Scholar
• World Health Organization. A Global Strategy to Eliminate Yellow Fever Epidemics (EYE) 2017–2026. World Health Organization; 2018. Available from: https://apps.who.int/iris/handle/10665/272408. Accessed January 19, 2023.
   Google Scholar
• Barrett ADT. Yellow Fever Vaccine: the Conundrum of 2 Doses, One Dose, or One-Fifth Dose to Induce and Maintain Protective Immunity. J Infect Dis. 2020;221(12):1922–1924. doi:10.1093/infdis/jiz379
   PubMed Web of Science ®Google Scholar
• World Health Organization. Fractional Dose Yellow Fever Vaccine as a Dose-Sparing Option for Outbreak Response; 2016.
   Google Scholar
• 17DD Yellow Fever Vaccine Package Insert. 2018.
   Google Scholar
• SAGE. Summary of the October 2016 Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE); 2016.
   Google Scholar
• World Health Organization. Global Advisory Committee on Vaccine Safety, 30 November – 1 December 2016. World Health Organization; 2017: Available from: https://apps.who.int/iris/handle/10665/253066. Accessed January 25, 2023.
   Google Scholar
• World Health Organization. Mass Yellow Fever Vaccination Campaign Launched in Democratic Republic of Congo. WHO Africa; 2016. Available from: https://www.afro.who.int/news/mass-yellow-fever-vaccination-campaign-launched-democratic-republic-congo. Accessed December 20, 2022.
   Google Scholar
• World Health Organization. Yellow Fever in Africa and the Americas, 2018. WHO. 2019;94(33):365–378
   Google Scholar
• Teitelbaum P, Bui YG, Libman M, McCarthy A. Fractional dosing of yellow fever vaccine during shortages: perspective from Canada. J Travel Med. 2018;25(1). doi:10.1093/jtm/tay098
   PubMedGoogle Scholar
• Yellow Fever Working Group. Interim Canadian recommendations for the use of a fractional dose of yellow fever vaccine during a vaccine shortage. Can Commun Dis Rep. 2016;42(8):158–160. doi:10.14745/ccdr.v42i08a02
   PubMedGoogle Scholar
• Theiler M, Smith HH. THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION. J Exp Med. 1937;65(6):787–800. doi:10.1084/jem.65.6.787
   PubMedGoogle Scholar
• Campi-Azevedo AC, de Almeida Estevam P, Coelho-dos-Reis JG, et al. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. BMC Infect Dis. 2014;14(1):391. doi:10.1186/1471-2334-14-391
   PubMedGoogle Scholar
• Department of Immunization, Vaccines and Biologicals. Fractional Dose Yellow Fever Vaccine as a Dose-Sparing Option for Outbreak Response: WHO Secretariat Information Paper; 2016.
   Google Scholar
• de Souza Lopes O, de Almeida Guimarães SSD, de Carvalho R. Studies on yellow fever vaccine III—dose response in volunteers. J Biol Stand. 1988;16(2):77–82. doi:10.1016/0092-1157(88)90034-0
   PubMedGoogle Scholar
• Roukens AH, Vossen AC, Bredenbeek PJ, van Dissel JT, Visser LG. Intradermally Administered Yellow Fever Vaccine at Reduced Dose Induces a Protective Immune Response: a Randomized Controlled Non-Inferiority Trial. PLoS One. 2008;3(4):e1993. doi:10.1371/journal.pone.0001993
   PubMed Web of Science ®Google Scholar
• Martins RM, Farias RHG. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccin Immunother. 2013;9(4):879–888. doi:10.4161/hv.22982
   PubMed Web of Science ®Google Scholar
• Juan-Giner A, Kimathi D, Grantz KH, et al. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. Lancet. 2021;397(10269):119–127. doi:10.1016/S0140-6736(20)32520-4
   PubMed Web of Science ®Google Scholar
• Casey RM, Harris JB, Ahuka-Mundeke S, et al. Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak — final Report. N Engl J Med. 2019;381(5):444–454. doi:10.1056/NEJMoa1710430
   PubMed Web of Science ®Google Scholar
• Tonacio AC, Do Nascimento Pedrosa T, Borba EF, et al. Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases. PLoS Negl Trop Dis. 2021;15(11):e0010002. doi:10.1371/journal.pntd.0010002
   PubMed Web of Science ®Google Scholar
• Roukens AHE, van Halem K, de Visser AW, Visser LG. Long-Term Protection After Fractional-Dose Yellow Fever Vaccination: follow-up Study of a Randomized, Controlled, Noninferiority Trial. Ann Intern Med. 2018;169(11):761. doi:10.7326/M18-1529
   PubMed Web of Science ®Google Scholar
• de Menezes Martins R, Maia LS, de Lima SMB, et al. Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study. Vaccine. 2018;36(28):4112–4117. doi:10.1016/j.vaccine.2018.05.041
   PubMed Web of Science ®Google Scholar
• Costa-Rocha IA, Campi-Azevedo AC, Peruhype-Magalhães V, et al. Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine. Front Immunol. 2019;10:1211. doi:10.3389/fimmu.2019.01211
   PubMed Web of Science ®Google Scholar
• Juan-Giner A, Namulwana ML, Kimathi D, et al. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial. Lancet Infect Dis. 2023;23(8):965–973. doi:10.1016/S1473-3099(23)00131-7
   PubMed Web of Science ®Google Scholar
• Kimathi D, Juan-Giner A, Orindi B, et al. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial. Lancet Infect Dis. 2023;23(8):974–982. doi:10.1016/S1473-3099(23)00114-7
   PubMed Web of Science ®Google Scholar
• Vasconcelos PFC, Barrett ADT. Are booster doses of yellow fever vaccine needed? Lancet Infect Dis. 2019;19(12):1275–1276. doi:10.1016/S1473-3099(19)30411-6
   PubMed Web of Science ®Google Scholar
• Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines. Vaccine. 2005;23(45):5205–5211. doi:10.1016/j.vaccine.2005.07.002
   PubMed Web of Science ®Google Scholar
• Roehrig JT, Hombach J, Barrett ADT. Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses. Viral Immunol. 2008;21(2):123–132. doi:10.1089/vim.2008.0007
   PubMed Web of Science ®Google Scholar
• Nnaji CA, Shey MS, Adetokunboh OO, Wiysonge CS. Immunogenicity and safety of fractional dose yellow fever vaccination: a systematic review and meta-analysis. Vaccine. 2020;38(6):1291–1301. doi:10.1016/j.vaccine.2019.12.018
   PubMed Web of Science ®Google Scholar
• Roukens AHE, Visser LG. Fractional dose yellow fever vaccination, coming of age. Lancet Infect Dis. 2023;23(8):889–890. doi:10.1016/S1473-3099(23)00205-0
   PubMed Web of Science ®Google Scholar
• Roukens AHE, Visser LG. Fractional-dose yellow fever vaccination: an expert review. J Travel Med. 2019;26(6):taz024. doi:10.1093/jtm/taz024
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO position on the use of fractional doses – June 2017, addendum to vaccines and vaccination against yellow fever WHO: position paper – June 2013. Vaccine. 2017;35(43):5751–5752. doi:10.1016/j.vaccine.2017.06.087
   PubMed Web of Science ®Google Scholar
• Ndeffo-Mbah ML, Pandey A. Global Risk and Elimination of Yellow Fever Epidemics. J Infect Dis. 2020;221(12):2026–2034. doi:10.1093/infdis/jiz375
   PubMed Web of Science ®Google Scholar
• Migliore A, Gigliucci G, Di Marzo R, Russo D, Mammucari M. Intradermal Vaccination: a Potential Tool in the Battle Against the COVID-19 Pandemic? RMHP. 2021;14:2079–2087. doi:10.2147/RMHP.S309707
   Google Scholar
• Clarke E, Saidu Y, Adetifa JU, et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia. Lancet Global Health. 2016;4(8):e534–e547. doi:10.1016/S2214-109X(16)30075-4
   PubMed Web of Science ®Google Scholar
• Więcek W, Ahuja A, Chaudhuri E, et al. Testing fractional doses of COVID-19 vaccines. Proc Natl Acad Sci USA. 2022;119(8):e2116932119. doi:10.1073/pnas.2116932119
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Desai S, Cravioto A, Nohynek H, Hombach J. Caution before fractionating COVID-19 vaccines. Nat Med. 2021;27(11):1856–1857. doi:10.1038/s41591-021-01534-z
   PubMed Web of Science ®Google Scholar